• 1
    Juniper EF & Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:7783.
  • 2
    Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial all_ergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94:182188.
  • 3
    Neumann Y, Bullinger M, Przybilla B. Quality of life in all_ergic rhinitis: standardisation of a self-assessment questionnaire. Allergy 1992;47 Suppl 12:72.
  • 4
    Heinisch M, Ludwig M, Bullinger M. Psychometrische Testung der Münchener Lebensqualitäts Dimensions Liste (MLDL). In: BullingerM, LudwigM, Von SteinbücherlN, editors. Lebensqualität bei kardiovaskulären Erkrankungen. Göttingen: Hogrefe, 1991:7390.
  • 5
    Huskisson EC. Measurement of pain. Lancet 1974;4:11271131.
  • 6
    Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983;16:87101.
  • 7
    Fähndrich E & Linden M. Zur Reliabilität und Validität der Stimmungsmessung mit der Visuellen Analog-Skala (VAS). Pharmacopsychiatrics 1982;15:9094.
  • 8
    Gaston-Johansson F, Johansson G, Sanne H. A comparative study of pain description, emotional discomfort and health perception in patients with chronic pain syndrome and rheumatoid arthritis. Scand J Rehab Med 1985;17:109119.
  • 9
    Dorow P, Aurich R, Petzold U. Efficacy and tolerability of azelastine nasal spray in patients with all_ergic rhinitis compared to placebo and budesonide. Arzneimittelforschung Drug Res 1993;43:909911.
  • 10
    Gastpar H, Dorow P, Aurich R, Petzold U. Investigation of long-term efficacy and tolerability of azelastine nasal spray in the treatment of perennial all_ergic rhinitis. Arnzneimittelforschnung Drug Res 1993;43:771776.
  • 11
    Golden SJ & Craig TJ. Efficacy and safety of azelastine nasal spray for the treatment of all_ergic rhinitis. J Am Osteopath Assoc 1999;99:712.
  • 12
    Herman D, Garay R, Le Gal M. A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int J Pediatr Otorhinolaryngol 1997;39:18.
  • 13
    Horak F, Bruttmann G, Pedrali P. A multicentric study of loratadine, terfenadine and placebo in patients with seasonal all_ergic rhinitis. Arnzneimittelforschnung Drug Res 1988;38:124128.
  • 14
    Kreutner W, Chapman RW, Gulbenkian A, Siegel MI. Antiall_ergic activity of loratadine, a non-sedating antihistamine. Allergy 1987;42:5763.
  • 15
    Ratner PH, Van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal all_ergic rhinitis. J Fam Pract 1998;47:118125.
  • 16
    Van Cauwenberge P & Juniper EF, and STAR Study Group. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal all_ergic rhinitis. Clin Exp Allergy 2000;30:891899.DOI: 10.1046/j.1365-2222.2000.00914.x
  • 17
    Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:742749.
  • 18
    Ellis AK, Day JH, Lundie MJ. Impact on quality of life during an all_ergen chall_enge research trial. Ann Allergy Asthma Immunol 1999;83:3339.
  • 19
    Bagenstose SE & Bernstein JA. Treatment of chronic rhinitis by an all_ergy specialist improves quality of life outcomes. Ann Allergy Asthma Immunol 1999;83:524528.
  • 20
    Badia X, Podzamczer D, Lopez-Lavid C, Garcia M. Evidence-based medicine and the validation of quality of life questionnaires: the Spanish version of the MOS-HIV questionnaire for the evaluation of the quality of life in patients infected with HIV. Enferm Infecc Microbiol Clin 1999;17:103113.
  • 21
    Myers C & Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res 1999;8:916.
  • 22
    Goodwin B, Bowers B, Hampel F, Cook C, Westlund R, Cox F. Superior improvement in disease-specific quality of life for SAR patients receiving intranasal fluticasone vs loratadine tablets [Abstract]. J Allergy Clin Immunol 1997;99:270.
  • 23
    Koop A, Gatermann C, Möges R. Benefit of handheld computers and WWW technologies in clinical multicenter trials and the care of patients with chronic diseases. Zentralbl Gynakol 2000;122:183186.